DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs

NCT01619111 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

105

Enrollment

OTHER

Sponsor class

Conditions

HER2-negative Metastatic Breast Cancer
HER2-positive Circulating Tumor Cells

Interventions

DRUG: standard chemo- or endocrine therapy
DRUG: standard chemo- or endocrine therapy + Lapatinib

Sponsor

Prof. Wolfgang Janni